| __timestamp | Incyte Corporation | Soleno Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 165772000 | 2917513 |
| Thursday, January 1, 2015 | 196614000 | 7878291 |
| Friday, January 1, 2016 | 303251000 | 8366794 |
| Sunday, January 1, 2017 | 366406000 | 6610381 |
| Monday, January 1, 2018 | 434407000 | 6556000 |
| Tuesday, January 1, 2019 | 468711000 | 6930000 |
| Wednesday, January 1, 2020 | 516922000 | 8758000 |
| Friday, January 1, 2021 | 739560000 | 10806000 |
| Saturday, January 1, 2022 | 1002140000 | 9844000 |
| Sunday, January 1, 2023 | 1161300000 | 13481000 |
| Monday, January 1, 2024 | 1242157000 |
Infusing magic into the data realm
In the competitive landscape of biotechnology, understanding spending patterns can offer valuable insights into a company's strategic priorities. Over the past decade, Incyte Corporation has consistently outpaced Soleno Therapeutics, Inc. in Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Incyte's SG&A expenses surged by over 600%, peaking at approximately $1.16 billion in 2023. In contrast, Soleno's spending increased by about 360%, reaching $13.5 million in the same year.
This stark difference highlights Incyte's aggressive investment in administrative and sales functions, potentially reflecting a robust growth strategy. Meanwhile, Soleno's more conservative spending may indicate a focus on lean operations or limited resources. As the biotech sector continues to evolve, these spending patterns could play a crucial role in shaping each company's future trajectory.
Operational Costs Compared: SG&A Analysis of Merck & Co., Inc. and Soleno Therapeutics, Inc.
Genmab A/S and Incyte Corporation: SG&A Spending Patterns Compared
Breaking Down SG&A Expenses: Incyte Corporation vs Pharming Group N.V.
SG&A Efficiency Analysis: Comparing Incyte Corporation and ADMA Biologics, Inc.
Operational Costs Compared: SG&A Analysis of Incyte Corporation and Merus N.V.
Incyte Corporation vs Soleno Therapeutics, Inc.: Strategic Focus on R&D Spending
Who Optimizes SG&A Costs Better? Incyte Corporation or Travere Therapeutics, Inc.
Incyte Corporation and MiMedx Group, Inc.: SG&A Spending Patterns Compared
Summit Therapeutics Inc. or Soleno Therapeutics, Inc.: Who Manages SG&A Costs Better?
Cost Management Insights: SG&A Expenses for Jazz Pharmaceuticals plc and Soleno Therapeutics, Inc.
CRISPR Therapeutics AG or Soleno Therapeutics, Inc.: Who Manages SG&A Costs Better?
Merus N.V. vs Soleno Therapeutics, Inc.: SG&A Expense Trends